Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,734 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06803693RecruitingPhase 2
New drug combo for untreated large B-cell lymphoma
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06801119RecruitingPhase 1
HN2301 for autoimmune diseases study
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Hefei, AnhuiAges 18–69 - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Anchorage, AlaskaAges 18 years+ - NCT06797401RecruitingPhase 2
RBD5044 for mixed high cholesterol and triglycerides
This trial tests a new medication called RBD5044 for people with mixed dyslipidemia (high levels of fats and cholesterol in the blood). It may help lower triglycerides and cholesterol when statins aren't enough.
LundAges 18–80 - NCT06798363RecruitingPhase 2/Phase 3
Testing different doses of propranolol for ulcerated hemangioma in children.
This trial tests different starting doses of oral propranolol to see which works best and is safest for treating infantile hemangiomas that have ulcers (sores). It may help your child heal faster.
Chengdu, SichuanAges Up to 1 year - NCT06794073Recruiting
Combination therapy for advanced liver cancer
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06797973RecruitingPhase 4
Morphine for pain after planned cesarean section
This trial studies whether giving a small dose of morphine into the spinal fluid during a planned cesarean section helps with pain after surgery. It aims to find a safe and effective way to manage pain for new mothers.
AarhusAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT06791291RecruitingPhase 2
Teplizumab for Japanese with early-stage type 1 diabetes
This trial tests an experimental drug called teplizumab to see if it can slow down or stop type 1 diabetes from getting worse. It is for Japanese people aged 1 to 34 who have stage 2 type 1 diabetes (blood sugar is slightly abnormal but not yet full diabetes).
Ichikawa, ChibaAges 1–34 - NCT06786624RecruitingPhase 3
Testing a new drug for depression that hasn't fully responded to treatment
This trial tests a new medication called NBI-1065845 added to your current antidepressant for people with depression that hasn't fully responded to treatment. It aims to see if this combination can better improve your symptoms.
Little Rock, ArkansasAges 18 years+ - NCT06784752RecruitingPhase 3
Testing a targeted radiation therapy for advanced neuroendocrine tumors
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Scottsdale, ArizonaAges 12–100 - NCT06791902Recruiting
Adaptive brain stimulation for walking problems in Parkinson's
This study tests a new type of deep brain stimulation (DBS) that automatically adjusts to your walking or balance issues. It uses your brain's own signals to improve movement.
Lausanne, Canton of VaudAges 18 years+ - NCT06782711Enrolling by invitation
Study of 3D-printed skull implants for bone loss repair
This trial tests a custom-made, 3D-printed skull implant to repair missing bone in the head (cranioplasty). It may help people who have a bone defect larger than 1 cm and are in generally good health.
Guadalajara, JaliscoAges 18 years+ - NCT06784921Recruiting
Study of sacituzumab govitecan for HER2-negative breast cancer
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
Hangzhou, ZhejiangAges 18–75 - NCT05219617RecruitingPhase 3
Carisbamate for frequent drop seizures in Lennox-Gastaut
This Phase 3 study tests whether carisbamate can reduce drop seizures in people with Lennox-Gastaut syndrome (LGS). It also checks whether the treatment is safe when added to existing seizure medicines.
Palo Alto, CaliforniaAges 4–55 - NCT05966493RecruitingPhase 2
Lufepirsen gel for persistent corneal epithelial defects
This Phase 2 trial tests whether a treatment gel called NEXAGON (lufepirsen) can improve healing and safety in people with a persistent corneal problem called PCED that hasn’t gotten better despite standard non-surgical treatments. You may be a candidate if your defect has lasted at least 2 weeks and hasn’t improved recently, and if you don’t have certain eye infections or other eye conditions.
Dothan, AlabamaAges 2 years+ - NCT06780137RecruitingPhase 1/Phase 2
Gocatamig plus ifinatamab deruxtecan for advanced small cell lung cancer
This study tests two new drugs (gocatamig and ifinatamab deruxtecan) for people whose small cell lung cancer has spread or come back after standard chemotherapy. It aims to see if the combination works better than current options.
Aurora, ColoradoAges 18 years+ - NCT06772168RecruitingPhase 3
New combo pill for diabetes and high cholesterol
This trial tests a new combination pill for people with type 2 diabetes and high cholesterol who are already on metformin. It aims to see if the new drug helps control both blood sugar and cholesterol better than current treatments.
AnyangAges 19–80 - NCT06778447Recruiting
Trial of disc tissue injection for degenerative disc disease
This study tests an experimental treatment that injects donated disc tissue (called an allograft) into damaged discs in your lower back. It's designed for people with chronic low back pain from disc degeneration who haven't found relief from non-surgical treatments.
Napa, CaliforniaAges 22–85 - NCT06779071Enrolling by invitationPhase 3
NPNP-001 injection for knee osteoarthritis pain
This study tests a new medicine called NPNP-001 for people with knee osteoarthritis who have not gotten enough relief from other treatments. The medicine is given as an injection into the knee to see if it can reduce pain and improve function.
SeoulAges 40 years+ - NCT06776861Recruiting
Radiation plus immunotherapy for advanced breast cancer
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06763965Enrolling by invitationPhase 1/Phase 2
BioTTT001 for recurrent high-grade glioma
This trial tests a new drug called BioTTT001 for people whose high-grade brain tumor has come back after standard treatment. The drug is given through a small device placed in the head to deliver it directly to the tumor area.
Beijing, Chaoyang DistrictAges 18 years+ - NCT06761066Enrolling by invitation
Testing NVP-NK4146 for mild cognitive impairment due to Alzheimer's
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
SeoulAges 60 years+ - NCT06766357RecruitingPhase 3
Cyclosporin gel for moderate to severe dry eye
This study tests a gel form of cyclosporine for people with moderate to severe dry eye that hasn't improved with other treatments. The gel is applied to the eye to help reduce inflammation and increase tear production.
Xiamen, FujianAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,734 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.